{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:41:41Z","timestamp":1792669301159,"version":"4.5.0"},"reference-count":9,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Data on ofatumumab use in women with multiple sclerosis (WwMS) planning pregnancy are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We conducted an observational study in WwMS to describe third-trimester CD19 counts, postpartum MS activity and pregnancy outcomes after pausing ofatumumab at conception.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-five women were included. Third-trimester CD19 counts remained depleted (median 0.017\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L) in 23 available results. No postpartum relapses occurred (25\/25 [100%]), and majority (22\/25 [88%]) had no new magnetic resonance imaging (MRI) activity. No new safety signals were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>B-cell depletion persisted into the third trimester following ofatumumab cessation for pregnancy with low postpartum MS activity, although limited by small sample.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261471448","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:41:58Z","timestamp":1784785318000},"page":"1334-1338","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["B-cell repopulation and postpartum MS disease activity following ofatumumab cessation for pregnancy in women with multiple sclerosis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7827-9933","authenticated-orcid":false,"given":"Denisse","family":"Bongol","sequence":"first","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"NIHR University College London Hospitals Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaleh","family":"Khaleeli","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Swanton","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-3750","authenticated-orcid":false,"given":"Ahmed","family":"Toosy","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"NIHR University College London Hospitals Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wilson","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chung","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-8902","authenticated-orcid":false,"given":"Wallace","family":"Brownlee","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"NIHR University College London Hospitals Biomedical Research Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh152"},{"key":"e_1_3_3_3_2","unstructured":"European Medicines Agency. KESIMPTA: Summary of product characteristics https:\/\/www.medicines.org.uk\/emc\/product\/12433\/smpc (accessed January 2026)."},{"key":"e_1_3_3_4_2","unstructured":"US Food and Drug Administration. KESIMPTA\u00ae (ofatumumab) prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125326s079lbl.pdf (accessed January 2026)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002060"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575197"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91655-9"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211101"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101137"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261471448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261471448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261471448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:06:58Z","timestamp":1792667218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261471448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/13524585261471448"],"URL":"https:\/\/doi.org\/10.1177\/13524585261471448","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}